Group 1 - The core viewpoint of the article is that Furuida (SH 600223) announced its financial performance for the first half of 2025, highlighting the revenue composition and market capitalization [1] - For the first half of 2025, Furuida's revenue composition is as follows: cosmetics accounted for 61.13%, property leasing for 16.37%, pharmaceuticals for 11.57%, additives for 9.98%, and other businesses for 0.95% [1] - As of the report, Furuida's market capitalization stands at 8.7 billion yuan [1]

Group 1 - The company achieved a revenue of 1.79 billion yuan in the raw materials and additives business during the first half of the year, with hyaluronic acid raw material sales reaching 1.16 billion yuan, a year-on-year increase of 23.4% [3] - The pharmaceutical business generated a revenue of 207 million yuan, with over 200 new county-level and OTC customer developments, focusing on core product upgrades [2] - The cosmetics segment reported a revenue of 1.094 billion yuan, with the Yilian brand achieving a revenue of 554 million yuan, reflecting a year-on-year growth of 23.78% [2] Group 2 - The company launched over 80 new products in the cosmetics sector, including the "Yier Doctor 287 mask" and "Yilian Purple Light Dual Extract Essence Water" [3] - The company has made significant advancements in technology, such as the innovative permeable collagen technology, which increased collagen subcutaneous penetration by 27.5 times [3] - The company is actively developing the "food and medicine homologous" business and has established cooperation with major clients to enhance raw material supply [2]

Core Insights - The company reported a revenue of 1.79 billion yuan in the first half of 2025, with a net profit of 108 million yuan, and total assets of 6.037 billion yuan as of June 30, 2025 [1][2] Group 1: Cosmetics Business - The cosmetics segment generated a revenue of 1.094 billion yuan in the first half of 2025, with the Yilian brand achieving 554 million yuan, reflecting a year-on-year growth of 23.78% [2] - The Yilian brand launched a global spokesperson, Zhang Linghe, and held a summer spray festival, with spray product line sales reaching 482 million yuan, an increase of 43% [2] - The Aier Doctor brand reported a revenue of 451 million yuan, with new products like the 287 mask and 287 lotion, generating nearly 10 million yuan in sales within two months of launch [2] Group 2: Pharmaceutical Business - The pharmaceutical segment achieved a revenue of 207 million yuan, expanding its client base by over 200 hospitals and OTC customers [2] - Key products include children's flu medication and a popular pain relief product recognized at the Wuzhen Health Conference [2] - The company is actively developing food-medicine integration standards and collaborating with major clients to enhance raw material supply [2] Group 3: Raw Materials and Additives - The raw materials and additives segment reported a revenue of 179 million yuan, with hyaluronic acid sales reaching 116 million yuan, a year-on-year increase of 23.4% [3] - Medical-grade hyaluronic acid sales surged by 287.3%, totaling 16.08 million yuan [3] - The overall gross margin for the hyaluronic acid business improved to 47.1%, up by 8.5 percentage points [3] Group 4: Innovation and R&D - The company launched over 80 new products in the cosmetics sector, including the Aier Doctor 287 mask and Yilian purple essence water [3] - The company introduced a pioneering transdermal collagen technology, enhancing skin penetration by 27.5 times [3] - The company has made significant progress in medical device registrations and drug development, including obtaining production licenses for various products [3]

Group 1 - The company FuRida (SH 600223, closing price: 8.57 yuan) announced on August 21 that it has appointed Ms. Dou Qianqian as the secretary of the board of directors, with her term aligned with the company's 12th board of directors [2] - For the first half of 2025, FuRida's revenue composition is as follows: cosmetics account for 61.13%, property leasing for 16.37%, pharmaceuticals for 11.57%, additives for 9.98%, and other businesses for 0.95% [2]

证券日报网讯 8月21日晚间，福瑞达发布公告称，公司于2025年8月20日召开了第十二届董事会第六次 会议，审议通过了《关于聘任公司董事会秘书的议案》，董事会同意聘任窦茜茜女士为公司董事会秘 书，任期与公司第十二届董事会一致。 （编辑 任世碧） ...

Core Viewpoint - The company, Lushang Freda Pharmaceutical Co., Ltd., reported a decline in revenue and profit for the first half of 2025, primarily due to challenges in the cosmetics and pharmaceutical sectors, including product iteration and pricing pressures from expanded procurement policies [1][2][3]. Company Overview and Financial Indicators - The company reported a total revenue of approximately 1.79 billion yuan for the first half of 2025, a decrease of 7.05% compared to the same period last year [2]. - The total profit for the period was approximately 153 million yuan, down 17.31% year-on-year [2]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was approximately 107.96 million yuan, reflecting a decrease of 15.16% [2]. - The total assets of the company at the end of the reporting period were approximately 6.04 billion yuan, showing a slight increase of 0.61% from the previous year [2]. Industry and Main Business Situation - The company operates in the cosmetics, pharmaceuticals, and raw materials sectors, with a focus on product innovation and market expansion [3][5]. - The domestic cosmetics market has shown signs of slowing growth, with retail sales growth of cosmetics lagging behind overall retail sales growth [3]. - The pharmaceutical sector is facing challenges due to expanded procurement policies and price reductions for winning products, impacting revenue generation [3][5]. Business Performance - The cosmetics segment reported a revenue of approximately 5.54 billion yuan, a year-on-year increase of 23.78%, while the brand "Aier Doctor" saw a significant revenue decline of 29.97% [10][11]. - The company has launched over 80 new products in the cosmetics sector during the reporting period, including key products from various brands [12][13]. - The pharmaceutical segment has been actively developing new products and enhancing brand visibility through participation in industry conferences and events [11][14]. Sales and Marketing Strategies - The company has established a comprehensive online and offline sales network, with online sales accounting for 84.20% of total revenue in the cosmetics segment [11]. - The marketing strategy includes leveraging social media and e-commerce platforms for brand promotion and customer engagement [10][11]. - The company is focusing on enhancing its product offerings and optimizing pricing strategies to improve market competitiveness [10][11]. Research and Development - The company has made significant advancements in research and development, particularly in the field of hyaluronic acid, which is widely used across various industries [3][8]. - The R&D efforts are supported by collaborations with academic institutions and the establishment of technology innovation systems [12][14]. - The company has received multiple certifications for its production facilities, emphasizing its commitment to quality and sustainability [15].

Core Points - The company reported a total asset of approximately 6.04 billion yuan, reflecting a slight increase of 0.61% compared to the previous year [1] - The operating revenue for the reporting period was approximately 1.79 billion yuan, showing a decrease of 7.05% year-on-year [1] - The total profit amounted to approximately 153.14 million yuan, which is a decline of 17.31% compared to the same period last year [1] - The net profit attributable to shareholders was approximately 0.11 yuan per share, down 15.38% from the previous year [1] Financial Summary - Total assets at the end of the reporting period were 6,037,060,817.19 yuan, compared to 6,000,330,923.23 yuan at the end of the previous year [1] - Operating revenue decreased from 1,925,374,405.82 yuan to 1,789,541,668.33 yuan [1] - Total profit decreased from 185,198,599.49 yuan to 153,143,384.43 yuan [1] - The net profit attributable to shareholders decreased from 0.13 yuan per share to 0.11 yuan per share [1] Shareholder Information - The largest shareholder, Shandong Commercial Group Co., Ltd., holds 51.62% of the shares, amounting to 524,739,200 shares [2] - Other significant shareholders include Shandong World Trade Center and LuShang Group Co., Ltd., holding 0.97% and 1.69% respectively [2] - The total number of shareholders at the end of the reporting period was 47,512 [1]

Core Viewpoint - The board of directors of Lushang Furuida Pharmaceutical Co., Ltd. held its sixth meeting of the twelfth session, where several key resolutions were passed regarding the company's financial report, action plans, risk assessments, and governance structure [1][2][3][4] Group 1: Financial and Operational Reports - The board unanimously approved the "2025 Semi-Annual Report" which reflects the company's financial status and operational results for the first half of 2025 [1] - The board also approved the "Semi-Annual Evaluation Report on the 'Quality Improvement and Efficiency Enhancement Return' Action Plan" [2] Group 2: Governance and Structural Changes - The board approved a proposal to cancel the supervisory board and amend the company's articles of association, allowing the audit committee to assume the supervisory functions [3] - A resolution was passed to revise and establish certain governance systems in accordance with relevant laws and regulations, reflecting the changes in the company's governance structure [4] - The board appointed Dou Qianqian as the company secretary, with her term aligned with the current board's term [2]

Core Viewpoint - The independent directors of Lushang Furuida Pharmaceutical Co., Ltd. convened a special meeting to review and approve a risk assessment report regarding Shandong Provincial Commercial Group Financial Co., Ltd., concluding that there are no significant deficiencies in its risk management [1][2]. Group 1 - The special meeting of the independent directors was held on August 19, 2025, and was legally valid as per relevant regulations [1]. - The independent directors unanimously approved the risk assessment report, which reflects the operational qualifications, internal controls, management, and risk management status of Shandong Provincial Commercial Group Financial Co., Ltd. [2]. - The report indicates that Shandong Provincial Commercial Group Financial Co., Ltd. is under strict supervision by the China Banking and Insurance Regulatory Commission, ensuring its business scope and internal risk control measures are adequately managed [2].

证券代码：600223 证券简称：福瑞达 编号：临 2025-025 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 8 月 29 日（星期五）14:00-15:00 ? 网络参与地址：上证路演中心平台（http://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络文字互动 ? 问题征集方式：投资者可于 2025 年 8 月 22 日（星期五）至 8 月 28 日 （星期四）16:00 前将需要了解的情况和相关问题通过电子邮件的形式发送至公 司投资者关系邮箱：lsfrd600223@163.com。公司将在业绩说明会上对投资者普 遍关注的问题进行回答。 鲁商福瑞达医药股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日披露 公司 2025 年半年度报告，为了便于广大投资者更全面深入地了解公司 2025 年上 半年业绩和经营情况，公司拟于 2025 年 8 月 29 日（星期五）14:0 ...